N
QNCX icon

Nuveen’s Quince Therapeutics QNCX Stock Holding History

Nuveen’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-299
Closed -$363K – 3445
2022
Q1 		$363K Sell
299
-79
-21% -$107K ﹤0.01% 3084
2021
Q4 		$954K Sell
378
-26
-6% -$159K ﹤0.01% 2876
2021
Q3 		$7.41M Sell
404
-83
-17% -$1.32M ﹤0.01% 1991
2021
Q2 		$5.16M Buy
487
+136
+39% +$1.14M ﹤0.01% 2230
2021
Q1 		$2.53M Sell
351
-25
-7% -$180K ﹤0.01% 2500
2020
Q4 		$2.09M Buy
376
+26
+7% +$230K ﹤0.01% 2488
2020
Q3 		$3.5M Sell
350
-22
-6% -$200K ﹤0.01% 2108
2020
Q2 		$3.44M Buy
372
+145
+64% +$1.33M ﹤0.01% 2093
2020
Q1 		$2.07M Buy
227
+4
+2% +$39.5K ﹤0.01% 2167
2019
Q4 		$2.5M Buy
223
+70
+46% +$422K ﹤0.01% 2330
2019
Q3 		$764K Buy
153
+76
+99% +$468K ﹤0.01% 2802
2019
Q2 		$654K Buy
+77
New +$460K ﹤0.01% 2914

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return

Nuveen's QNCX Position: Q2 2022 in Review

Nuveen sold out of Quince Therapeutics (QNCX) in Q2 2022, closing a stake of 299 shares — an estimated $363K sold.

Nuveen first reported a position in QNCX in Q2 2019 and held it in 12 quarters. The position peaked at $7.41M in Q3 2021. 66 funds tracked by Wall St. Rank hold QNCX as of Q2 2022.

  • Nuveen reported no remaining Quince Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Nuveen sold 299 Quince Therapeutics shares in Q2 2022, an estimated $363K.
  • Nuveen first reported a position in Quince Therapeutics in Q2 2019 and held it in 12 quarters.
  • Nuveen's Quince Therapeutics position peaked at $7.41M in Q3 2021.
  • 66 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2022.

Based on Nuveen's 13F filing for Q2 2022, filed 15 Aug 2022.